Advertisement

Clinical Trial Corner

Phase 3 Trial of Fablyn Plus Verzinio for Metastatic Breast Cancer Initiates Registration

March 20th 2023

Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.

Trial of Plinabulin, Keytruda, Docetaxel Kicks Off in Lung Cancer

March 1st 2023

The first patient was enrolled in a three-drug clinical trial, which researchers hope will lend insight into immunotherapy resistance in lung cancer.

Ovarian Cancer Trial to Study IMNN-001, Chemotherapy Combination

February 27th 2023

The first patient has been enrolled in a clinical trial evaluating IMNN-001, an immunotherapy, combined with Avastin for the treatment of advanced ovarian cancer.

Phase 2 Trial Investigating New Hormone-Based Drug for Breast Cancer

February 25th 2023

Researchers are recruiting patients with ER-positive, HER2-negative breast cancer to participate in a trial evaluating (Z)-endoxifen.

Ointment Being Studied for Hand-Foot Skin Reaction Related to Kidney Cancer Treatment

February 21st 2023

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

Padcev to Be Studied in Advanced Bladder Cancer

February 17th 2023

A clinical trial just kicked off, analyzing Padcev in patients with advanced, unresectable bladder cancer.

First Patients Dosed With Novel Inhibitor in Trial on Relapsed or Refractory AML Subset

February 11th 2023

Researchers conducting a phase 2 trial recently dosed the first patients with a novel menin inhibitor for the treatment of patients with NPM1-mutant relapsed or refractory acute myeloid leukemia.

Novel Drug to Be Studied in Ovarian Cancer

February 10th 2023

After promising phase 1 results, ART0380 will be studied in a randomized phase 2 trial for patients with platinum-resistant ovarian cancer.

Direct-to-Bladder Immunotherapy Drug to Be Studied in Bladder Cancer

February 1st 2023

The first patient was dosed with lerapolturev in a phase 1/2 clinical trial evaluating the drug in patients with bladder cancer and other solid tumors.

Trial to Investigate If Novel Drug Combo Can Boost Outcomes in Lung Cancer

January 31st 2023

A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.

First Patient Injected With Novel Radiotherapy in Phase 2b Trial for Brain Cancer

January 28th 2023

The treatment previously demonstrated significantly improved overall survival for patients with recurrent glioblastoma in a phase 1 study.

Trial to Investigate Novel Drug in KRAS-Mutant Lung Cancer

January 27th 2023

VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.

Iadademstat-Placebo Combo to Be Studied in Neuroendocrine Cancers

January 26th 2023

Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.

Novel Drug to Be Tested in Rare Form of Eye Cancer

January 24th 2023

A phase 2 study will investigate the efficacy of darovasertib for patients with uveal melanoma and whether the drug can potentially result in lower radiation doses or fewer eye removal surgeries.

First Patient with Colorectal Cancer Received Nanrilkefusp Alfa in Phase 2 Trial

January 21st 2023

The multicenter study is evaluating the safety and efficacy of nanrilkefusp alfa combined with Erbitux.

Cancer-Fighting Virus to Be Studied in Pancreatic Cancer Subtype

January 19th 2023

An oncolytic virus engineered to kill cancer cells was administered to a patient with pancreatic ductal adenocarcinoma as part of a phase 2b trial.

First Patient Dosed with AVB-001 in Trial for Relapsed Refractory Ovarian Cancer

January 19th 2023

The trial is evaluating the safety and efficacy of AVB-001 patients with relapsed refractory ovarian cancer.

New KRAS Inhibitor to Be Studied in Lung, Colon and Pancreatic Cancers

January 18th 2023

The COVALENT-102 trial will investigate BMF-219 in patients with non-small cell lung cancer, colorectal and pancreatic cancers.

First Patient Receives Keytruda Combination in Ovarian Cancer Trial

January 6th 2023

Investigators have administered Keytruda and ONC-392 the first patients with platinum resistant ovarian cancer.

Trial Receives FDA Green Light to Proceed Evaluating EVX-01, Keytruda Combo in Metastatic Melanoma

January 5th 2023

A phase 2 trial evaluating EVX-01 plus Keytruda (pembrolizumab) in patients with metastatic melanoma may continue, the FDA said.

Phase 1 Trial to Test if Two Drugs Can Work Together to Treat Patients with RAS/MAPK Pathway-Driven Cancers

January 3rd 2023

Promising early clinical data about the drugs ERAS-007 and ERAS-601 has led to a trial studying the combination of the two drugs in treating patients with RAS/MAPK pathway-driven cancers.

Zolbetuximab and Chemotherapy Combination Demonstrates Positive Results for Some Patients with Gastric Cancers, According to Results from Phase 3 Trial

January 2nd 2023

The combination met its main goal of progression-free survival and secondary goal of overall survival.

Researchers Hope a New Drug Can Help Overcome Immunotherapy Resistance in Metastatic Cancers

December 2nd 2022

A recently launched clinical trial of NTX1088 will determine if the novel drug can help overcome immune checkpoint inhibition resistance in patients with locally advanced or metastatic solid tumors.

Phase 1 Trial Will Analyze a Direct-to-Brain Drug for Recurrent Glioblastoma Treatment

November 16th 2022

The first patient was enrolled in a phase 1 trial analyzing MTX110 in patients with recurrent glioblastoma, an aggressive type of brain cancer.

FDA OKs Clinical Trial for Novel Neuroendocrine Carcinoma Drug

November 10th 2022

A phase 2 clinical trial will evaluate iadademstat for patients with relapsed or refractory high-grade neuroendocrine carcinoma.

Clinical Trial Kicks Off Evaluating a New Drug for a Group of Solid Cancers

November 4th 2022

A novel drug, MRT-2359, will be studied in a phase 1/2 trial for patients with MYC-driven cancers.

Novel Drug to Be Investigated for Breast Cancer Treatment-Related Hot Flashes

November 3rd 2022

Patients with breast cancer can enroll on a clinical trial analyzing elinzanetant for endocrine therapy-related hot flashes.

Guided Radiation Technique Will Be Studied in Phase 3 Pancreatic Cancer Trial

November 2nd 2022

A clinical trial will determine if chemotherapy plus 5-fraction MRIdian SMART will improve survival over chemotherapy alone in patients with locally advanced pancreatic cancer.

Study Assessing Safety, Efficacy of Experimental Treatment in Metastatic Prostate Cancer Adds Additional Trial Sites

October 27th 2022

The study investigators will review the efficacy of [Lu-177]-PNT2002, a radioligand treatment, compared with Zytiga or Xtandi in patients with metastatic castration-resistant prostate cancer.

Lumakras-Novel Drug Combination to Be Studied in KRAS-Mutant Lung Cancer, Solid Tumors

October 19th 2022

A clinical trial recently kicked off to study the effects of combining the novel drug BBP-398 plus Lumakras in patients with lung cancer that harbors a KRAS G12 mutation.

First Patient Receives Investigational CAR-T Cell Therapy in Trial Assessing the Treatment for Lymphoma, Leukemia

October 14th 2022

Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.

Trial to Investigate if a Novel Drug Can Foster Keytruda Effectiveness in Solid Cancers

October 11th 2022

NC410 plus Keytruda will be studied in a phase 1b/2 trial for patients with certain solid cancers that either did not respond to or have not been treated with an immunotherapy agent.

FDA Fast Tracks Investigational Drug With or Without Keytruda for Possible Approval for Head and Neck Cancer

October 10th 2022

The FDA granted a fast track designation to an investigational drug alone and in combination with Keytruda to treat patients with HPV recurrent/metastatic head and neck squamous cell carcinoma.

FDA Fast Tracks Investigational Drug for Potential Approval in Lung Cancer Subtype

October 4th 2022

Treatment with an investigational drug elicited a median progression-free survival (time from treatment until disease progression or death) of 8.9 months among patients with a form of unresectable or metastatic squamous non-small cell lung cancer, according to trial findings.

Early-Phase Trial to Study Novel Drug, With or Without Keytruda, in Solid Cancers

September 27th 2022

The novel drug PY159 will be studied as a single agent and in combination with Keytruda for patients with certain solid tumors — including ovarian, pancreatic, lung, head and neck, colorectal and breast cancers.

Phase 3 Trial to Study an Immunochemotherapy Regimen in Platinum-Resistant/Refractory Ovarian Cancer

September 26th 2022

The OnPrime trial will investigate if adding Olvi-Vec, a modified virus, to chemotherapy and Avastin will improve outcomes for pretreated platinum-resistant or refractory ovarian cancer.

Studies Will Investigate Novel Drug in Colon and Skin Cancer

September 16th 2022

Botensilimab will be evaluated in certain patients with colorectal cancer and melanoma, a type of skin cancer, in two recently launched clinical trials.

Phase 2 Trial to Study Novel Drug in Pretreated Solid Tumors

September 8th 2022

The first patient was treated in a phase 2 trial assessing the safety and efficacy of navicixizumab, with or without chemotherapy, in colorectal, gastric, ovarian and breast cancer.

New Drug to Be Investigated for Chemotherapy-Induced Peripheral Neuropathy

September 2nd 2022

ATX01, a new topical treatment for chemotherapy-induced peripheral neuropathy, will be investigated in a phase 2 trial.

Early Findings of Novel Agent Show Promise in Treating Rare Blood Cancer

August 31st 2022

Patients with blastic plasmacytoid dendritic cell neoplasms can enroll in the ongoing CADENZA trial, which is investigating the safety and efficacy of the novel agent pivekimab sunirine in patients with the rare blood cancer.

Novel Drug Will Be Evaluated for EGFR-TKI—Mutant Lung Cancer

August 31st 2022

The first patient has been treated with H002, a novel drug being investigated for non-small cell lung cancer that is resistant to a prior EGFR TKI treatment.

Study Will Analyze Imetelstat-Jakafi Combination for Myelofibrosis

August 30th 2022

A clinical trial recently kicked off, analyzing the combination of imetelstat plus Jakafi for the treatment of myelofibrosis, a type of rare blood cancer.

Trial for At-Home Colorectal Cancer Test Completes Enrollment of More Than 10,000 Patients

August 26th 2022

Many participants enrolled in the CRC-PREVENT trial are from communities often underrepresented in clinical trials due to gender, race and socioeconomic status, among other factors.

Enrollment Opens for Trial Evaluating Abelacimab for Blood Clots From Gastrointestinal, Genitourinary Cancers

August 26th 2022

The phase 3 MAGNOLIA trial will assess whether abelacimab can prevent venous thromboembolism recurrence in patients with gastrointestinal or genitourinary cancers.

First Patient Receives Investigational Cancer Drug-Combination for Relapsed/Refractory Acute Myeloid Leukemia

August 22nd 2022

Adding the investigational cancer drug lanraplenib to Xospata, if found to be effective, may broaden treatment options for patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

First Patient Receives Treatment With Investigational CAR-T Cell Therapy-Opdivo Combo for Hodgkin Lymphoma

August 18th 2022

A representative of the company developing the investigational CAR-T cell therapy noted that they hypothesize that the combination “has the potential to further enhance efficacy and provide patients with a chemotherapy-sparing, second-line treatment option.”

New Study to Explore Safety and Efficacy of a Single-Infusion CAR-T Cell Treatment in Patients With Colon Cancer

August 18th 2022

Investigators plan to analyze if treatment with an experimental, CAR-T cell therapy is safe and effective in a small group of patients with relapsed or refractory metastatic colorectal cancer.

Study to Investigate if Exercise Improves Outcomes, Decreases Chemo Side Effects in Colon Cancer

August 16th 2022

A new study will analyze the effect of exercise on chemotherapy tolerability and outcomes in patients with colon cancer.

Study to Investigate If Novel Drug Overcomes PARP Inhibitor Resistance in Breast Cancer

August 15th 2022

A phase 2 trial will analyze the novel drug ART4215 with Talzenna, a PARP inhibitor, for patients with BRCA-deficient breast cancer.

Patient Enrollment Expands in Trial Evaluating Novel Drug in Breast Cancer

August 12th 2022

After findings from an early-phase trial showed that the novel drug was associated with anti-tumor activity, investigators decided to continue enrolling more patients with ER-positive, HER2-negative metastatic breast cancer.

Investigational Drug-Libtayo Combo Demonstrates Clinical Activity in Metastatic Prostate Cancer

August 8th 2022

Treatment with an investigational drug plus with Libtayo showed encouraging anti-tumor activity in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary data from an early-phase trial.

Trial to Compare Safety and Efficacy of Novel Cell Therapy to Standard of Care in Patients With Rare Blood Cancers

August 3rd 2022

Enrollment has begun on a phase 3 clinical trial assessing the safety and efficacy of an investigational cell therapy in patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes.

Novel Drug to Be Investigated With Keytruda in Advanced Solid Cancers

July 27th 2022

A new treatment group within the PYNNACLE clinical trial is set to evaluate a novel drug plus Keytruda in patients with p53 Y220C-mutant locally advanced or metastatic solid tumors.

Padcev Plus Keytruda Elicits Encouraging Results in Metastatic Bladder Cancer

July 27th 2022

More than half of patients with metastatic, cisplatin-ineligible bladder cancer saw their cancer shrink when given Padcev and Keytruda in a clinical trial.

Study Will Investigate If Giving Chemo Before and After Surgery Can Boost Gallbladder Cancer Outcomes

July 25th 2022

An ongoing clinical trial aims to determine if pre- and post-surgical chemotherapy can improve outcomes for patients with stage 2 and 3 gallbladder cancer.

Trial Will Investigate Drug to Curb Cancer Treatment-Related Anorexia, Weight Loss

July 19th 2022

ART27.13 may help increase appetite in patients undergoing cancer treatment.

Amazon and Fred Hutch Partner to Investigate Safety, Efficacy of Cancer Vaccine

July 14th 2022

Amazon and Fred Hutchinson Cancer Center recently launched an early-phase clinical trial to assess the safety and efficacy of a cancer vaccine in the treatment of patients with late-stage skin cancer or hormone receptor-positive, HER2-negative breast cancer.

Trial Launched to Investigate Novel Triplet Therapy in Treatment of Rare Gastric or Esophageal Cancer

July 13th 2022

The manufacturer of one of the cancer treatments announced that it is also participating in clinical trials assessing the safety and efficacy of their product in colorectal and endometrial cancer.

Study Launches to Investigate Effectiveness of Potential First-in-Class Lung Cancer Drug

July 11th 2022

The first patient was dosed in a phase 2 trial studying the efficacy of sapanisertib in patients with NRF2-mutant relapsed/refractory lung cancer.

Study to Investigate Safety, Efficacy of Novel Cell Therapy Plus Chemo in Cancer That Spread to the Abdominal Cavity

July 7th 2022

According to the manufacturer, this is the first-in-human clinical trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers.

New Drug Will Be Studied in Relapsed/Refractory Myeloma, Other Blood Cancers

July 6th 2022

The myeloma treatment group of the COVALENT-101 clinical trial recently started, analyzing the new drug BMF-219 in patients with relapsed or refractory disease.

FDA Permits the Study of a Novel Cancer Drug for Multiple Solid Tumors to Continue

June 30th 2022

The study the FDA allowed to continue is investigating the safety and efficacy of the novel cancer drug ACR-368 in patients with endometrial, urothelial and ovarian cancer.

Novel Drug-Tecentriq Combo to Be Studied in Non-Small Cell Lung Cancer

June 17th 2022

A phase 2a trial is kicking off to study frontline GB1211 with the immunotherapy agent Tecentriq in patients with advanced or metastatic non-small cell lung cancer.

Investigators Launch Study to Review Novel Cancer Vaccine in Patients With Advanced Solid Tumors

May 26th 2022

A clinical trial just launched to study Vaxinia — a novel cancer vaccine — in patients with previously treated advanced solid tumors.

Trial Will Investigate Drug Duo in Solid Cancers With MAPK Pathway Aberrations

May 25th 2022

Patients can still talk to their clinicians about enrolling in a sub-study of the FIRELIGHT-1 trial, analyzing tovorafenib plus pimasertib in progressive or refractory solid tumors with MAPK pathway aberrations.

Clinical Trial to Assess Experimental Drug as Single-Agent, and Combined With Keytruda Across Several Solid Tumors Launches

May 25th 2022

The aim of the early-stage trial is to identify the safety of the experimental drug as either a single-agent therapy as well as in combination with Keytruda in adults with multiple solid tumors.

Trial Launches to Study a New Drug for B-Cell Malignancies

May 20th 2022

NX-5948 may be able to pass through the blood-brain barrier in patients with B-cell malignancies, potentially making it a promising option for patients with disease in their central nervous system.

Cancer Trial Hopes to Find New Patient Populations That Will Respond to Already-Approved Drugs

May 19th 2022

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

Trial Kicks Off to Study Experimental CAR-T Cell Therapy in Myeloma

May 18th 2022

The hope, according to an expert, is that this trial will expand CAR-T cell therapy access to more patients with multiple myeloma.

Talzenna-Novel Drug Combo Continues to Be Studied in Patients With Triple-Negative Breast Cancer

May 12th 2022

Findings from an early-stage trial assessing Talzenna in combination with a novel drug, known as ZEN-3694, have led the manufacturer to initiate a later-stage study in patients with triple-negative breast cancer.

First-in-Human Trial Assessing Novel Drug in Patients With Solid Tumors Launches

May 12th 2022

The primary objective of the early-stage trial is to determine the maximum tolerated dose of the novel drug in a group of patients with recurrent and/or refractory solid tumors.

Can a Virtual Reality Program Reduce Chronic Pain From Cancer?

May 10th 2022

Researchers are set to launch a new study to examine the feasibility of using an in-home virtual reality-guided mindfulness program to mitigate the effects of chronic cancer-related pain in patients and cancer survivors.

Trial Kicks Off to Evaluate CycloSam for Sarcoma and Cancer that Spread to the Bone

May 4th 2022

The first patient was dosed in a clinical trial evaluating the radiopharmaceutical agent, CycloSam, in patients with bone cancer or cancer that has metastasized to the bone.

Trial for Waldenstrom’s Macroglobulinemia Treatment Will Continue, as Early Data Yields Promising Results

May 2nd 2022

The trial of CLR 131 (iopofosine) for relapsed/refractory Waldenstrom’s macroglobulinemia will continue, as the drug will be studied in an estimated 50 patients.

Launching of Early-Phase Trial May Mark a ‘Major Milestone’ for Improving Gastric and Pancreatic Cancer Treatment

April 27th 2022

The first patient was dosed in the CLAUDIO-01 trial, analyzing SOTO102 in patients with certain types of gastric and pancreatic cancers.

Patient Receives Treatment With Novel Drug in First-in-Human Trial Assessing its Safety and Efficacy in Brain and Lung Cancer

April 25th 2022

The drug, known as BDTX-1535, is being investigated in patients with glioblastoma that harbors EGFR alterations and non-small cell lung cancer that harbors EGFR mutations of intrinsic or acquired resistance and disease that has failed standard treatment.

First Patient Treated in Study to Determine Tolerability, Dosing of Investigational Drug in Certain Solid Tumors

April 22nd 2022

Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.

Early-Phase Trial to Investigate Novel CAR-T Cell Therapy Alongside Oncolytic Virus in Recurrent Brain Cancer Set to Launch

April 18th 2022

The plan to launch the phase 1 trial to evaluate the safety and efficacy of combining the CAR-T cell therapy and oncolytic virus in patients with recurrent glioblastoma, a type of brain cancer, is supported by interim data from two ongoing trials.

Pharma Company Stops Patient Enrollment in Ewing Sarcoma Trial to Prioritize Development of a Blood Cancer Drug

April 15th 2022

The plan, according to the San Diego-based pharmaceutical company, is to launch a phase 3 trial to analyze the safety and efficacy of a novel drug in mantle cell lymphoma in the second half of 2022.

Trial to Evaluate Safety, Efficacy of Novel Drug for Various Solid Tumors Treats First Patient

April 15th 2022

The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.

FDA OKs Continued Enrollment in Ongoing Blood Cancer Clinical Trials After Gilead Addresses Safety Concerns

April 15th 2022

Earlier in the year, clinical trials assessing magrolimab for myelodysplastic syndrome and acute myeloid leukemia were put on a partial clinical hold, but now the FDA said that they can start enrolling patients again.

FDA Speeds Up Development of New Metastatic Breast Cancer Treatment

April 14th 2022

The Food and Drug Administration granted a fast-track designation to Bria-IMT for the treatment of patients with metastatic breast cancer.

Clinical Trial Assessing Keytruda-Investigational Drug Combo in Head and Neck, Bladder and Lung Cancer Doses First Patient

April 13th 2022

Investigators plan to enroll approximately 90 patients with squamous cell carcinoma of the head and neck, as well as metastatic bladder and non-small cell lung cancer.

Trial of Direct-to-Tumor Skin Cancer Drug Doses First Patient

April 7th 2022

A phase 2 trial will investigate LTX-315 in patients with basal cell carcinoma, the most common form of skin cancer.

First-in-Human Trial of an Investigational Cell Therapy for Advanced Gynecologic Cancers Treats First Patient

April 7th 2022

The first patient was dosed in an early-phase trial evaluating the investigational cell therapy DeTIL-0255 for the treatment of advanced ovarian, cervical and endometrial cancer.

Novel Treatment Given to First Patient in Trial Assessing the Drug’s Safety and Efficacy in Solid Tumors With Certain Genetic Alterations

April 6th 2022

Researchers have treated the first patient in the PRECISION 1 trial with Fyarro to assess the drug’s efficacy across several endpoints including survival among more than 100 patients with solid tumors that exhibit certain genetic alterations.

Can a Skin Patch Effectively Control Chemotherapy-Induced Nausea, Vomiting?

April 6th 2022

An upcoming phase 2 study will explore if the transdermal (through the skin) delivery of a drug commonly used to treat nausea and vomiting will result in no nausea, no vomiting and no use of rescue medicines in patients with cancer receiving chemotherapy.

First Patient With Lymphoma Receives Novel Cell Therapy in Large-Scale Trial

April 5th 2022

The plan is to assess the safety and efficacy of the genetically engineered cell therapy alongside high-dose chemotherapy and blood stem cell transplantation in approximately 150 patients with lymphoma.

First Patient Receives Novel Antibody in Early-Phase Trial Assessing Safety, Efficacy of the Drug in Several Solid Tumor Types

April 4th 2022

A patient with an advanced solid tumor was given their first dose of a novel antibody, kicking off a phase 1/1b study comparing this drug with or without Keytruda in patients with several types of solid tumors.

Early-Stage Clinical Trial Treats First Patient With Life-Threatening Cancer Metastases With Investigational Drug

March 30th 2022

It is expected that up to 18 patients with leptomeningeal metastases — a serious form of cancer that has spread from its original location to an area surrounding the brain and spinal cord — will receive treatment with the investigational drug.

First Patient Enrolled Onto Study Evaluating Zepzelca Monotherapy for Treatment of Certain Solid Tumors

March 29th 2022

Approximately 60 patients with metastatic/unresectable solid tumors, including bladder cancer, are expected to be enrolled onto a clinical trial assessing the safety and efficacy of Zepzelca.

Clinical Trial Investigating a Combo Therapy in Brain Cancer Now Enrolling Patients

March 28th 2022

The study authors plan to enroll 24 patients with glioblastoma, an aggressive brain tumor, to assess the efficacy an investigational drug plus Libtayo prior to surgery to remove the tumor.

First Patient Dosed in Early-Phase Trial Investigating a New Drug for Bladder Cancer

March 25th 2022

The trial will be testing TARA-002 in patients with non-muscle invasive bladder cancer with high-grade carcinoma in situ and high-grade papillary tumors.

Novel Drug-Keytruda Combo Meets Goal for Kidney Cancer Outcomes Before Trial Enrollment Ends

March 24th 2022

MRX0518 plus Keytruda led to a clinical benefit in four out of 16 evaluable patients with renal cell carcinoma. The drug duo will continue to be studied for multiple types of solid tumors.

Trial to Assess Efficacy of Test to Detect Cancer Recurrence Across a Plethora of Solid Tumors Enrolls First Patient

March 18th 2022

Approximately 100,000 patients with stage 1 to stage 3 solid tumors will be enrolled onto the trial across 25 sites, according to the manufacturer of the test aimed at detecting cancer recurrence.

FDA Clears The Way For a Trial to Evaluate an Investigational Drug Plus Keytruda in Treatment of Solid Tumors

March 17th 2022

The early-stage trial, according to the investigational drug’s manufacturer, Adagene, is expected to take place across multiple sites in the United States and Asia Pacific.

Clinical Trial Testing Novel Treatment With Standard-of-Care Chemotherapy in Patients With Pancreatic Cancer Expands to New Location

March 16th 2022

Four sites across the United States are enrolling patients with locally advanced or metastatic pancreatic cancer to see if a novel drug combined with standard-of-care chemotherapy bests chemotherapy alone in survival outcomes and responses to treatment.

Trial to Assess Safety and Efficacy of Novel Drug for Extremely Rare Cancer Begins Enrolling Patients

March 10th 2022

The rare cancer, known as adenoid cystic carcinoma, is diagnosed in fewer than 1,500 people in the United States each year and is often found in the salivary glands, a part of the body associated with helping a person swallow and digest food.

Patient Enrollment Begins for Trial Assessing Novel Treatment Combo in Pancreatic Cancer

March 4th 2022

The study authors plan to enroll 32 patients with advanced pancreatic cancer into the trial to assess the efficacy and safety of an experimental treatment combination.

Photoimmunotherapy Trial Begins in Certain Patients With Head and Neck, and Skin Cancer

February 22nd 2022

The goal of the phase 2 trial is to study the safety and efficacy of ASP-1929, a photoimmunotherapy with fluorescence imaging, in patients with head and neck or skin cancer.

Trial Initiated to Study Protein-Inhibiting Treatment Option for Patients With Acute Leukemia

February 17th 2022

A trial to examine BMF-219 in patients with relapsed or refractory acute leukemias has begun recruiting patients across multiple U.S. states.

Clinical Trial Testing Effectiveness of LOXO-305 in Mantle Cell Lymphoma Now Open to Patients

February 9th 2022

A phase 3 trial evaluating the safety and efficacy of the BTK inhibitor LOXO-305 in patients with previously treated mantle cell lymphoma is now open to patients across more than a dozen states.

Trial for Brain Cancer Immunotherapy Treatment Opens

February 7th 2022

A phase 2b clinical trial evaluating the efficacy and safety of an immunotherapy drug for patients with brain cancer has opened at Roswell Park Comprehensive Cancer Center in Buffalo, New York, with additional plans to be carried out at more than a dozen sites.

Trial Underway for Novel Agent Plus Immunotherapy for HPV-Related Head and Neck Cancer

February 2nd 2022

After preliminary results showed promise for the combination, researchers are expanding their clinical trial for PDS0101 plus Keytruda in HPV-related head and neck cancer.

Trial Launches to Assess Novel Immunotherapy Approach in Metastatic Prostate Cancer

February 1st 2022

A phase 1/2a clinical trial examining the effects of a treatment called LAVA-1207 for patients with metastatic prostate cancer has now begun.

First Allogeneic RNA Cell Therapy Clinical Trial Begins in Multiple Myeloma

January 27th 2022

A clinical trial to evaluate Descartes-25, a novel allogeneic RNA cell therapy, for multiple myeloma has officially treated its first patient and is now recruiting in certain locations.

Can a Blood Test Detect Lung Cancer in High-Risk Adults?

January 19th 2022

A new study to evaluate the accuracy of a blood test for detecting lung cancer in high-risk adults has enrolled its first participant with plans to enroll thousands more.

Enrollment Begins for First-Line Maintenance Vaccine for Metastatic CRC

January 13th 2022

Enrollment has begun for a trial evaluating a vaccine as first-line maintenance treatment for metastatic, microsatellite-stable colorectal cancer.

Trial Underway for Potential First Treatment Option of Newly Diagnosed NPM1-Mutant AML

January 12th 2022

A phase 3 trial has begun to examine entospletinib, a selective inhibitor, as a treatment for patients with newly diagnosed NPM1-mutated acute myeloid leukemia.

Trial Launched to Assess Safety and Efficacy of Novel Drug in Rare Type of Head and Neck Cancer

January 10th 2022

A phase 2 trial was recently launched to examine the safety and efficacy of oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma.

Trial Underway to Assess Efficacy of Novel Radiopharmaceutical Drug in Neuroendocrine Tumors

January 5th 2022

The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.

5 Cancer Clinical Trials You May Have Missed

December 18th 2021

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

Oncolytic Virus Clinical Trial Opens for Patients With Advanced Breast Cancer

December 17th 2021

City of Hope has opened its first-in-human clinical trial for an investigational therapy in patients with advanced breast cancer.

Novel Therapy Being Assessed for the Treatment of RAF-Altered Solid Tumors

December 3rd 2021

Investigators plan to analyze the safety and efficacy of a novel cancer therapy for the treatment of patients with RAF-altered solid tumors.

First Patient Randomized in Phase 2 Trial for NSCLC Treatment Combination

December 1st 2021

The first patient was randomized in the phase 2 trial examining Tedopi and Opdivo for non-small cell lung cancer.

Expansion of IOA-244 Trial Fully Enrolled for Uveal Melanoma

November 26th 2021

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

Phase 2 Trial Initiated for Second Line Treatment of AML and MDS

November 18th 2021

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

CAR-T Cell Therapy Trial Currently Enrolling Patients With CLL and SLL

November 16th 2021

The TRANSCEND CLL 004 trial is currently enrolling patients to determine the efficacy of a CAR-T cell therapy.

First Patient Receives Novel Immunotherapy in Bladder Cancer Sub-Study

November 13th 2021

The first patient with bladder cancer was dosed in a phase 1/2 trial examining responses to an investigational immunotherapy.

Enrollment Begins in Devimistat Trial for Patients With Relapsed Clear Cell Sarcoma

November 12th 2021

The first patient has been enrolled in the APOLLO 613 Phase 1/2 clinical trial for CPI-613.

Study Initiated for Bispecific Antibody in Patients With T-cell Lymphoma

November 10th 2021

A phase 1 trial of ONO-4685 was initiated for the evaluation of the antibody in patients with relapsed or refractory t-cell lymphoma.

BOLD-100 Trial Receives FDA Clearance for Treatment of Advanced GI Cancers

November 4th 2021

The Food and Drug Administration gave clearance to Bold Therapeutics for a phase 1b/2a trial examining treatments for advanced GI cancers.

Patients Dosed in Trial of Topical Gel for Dose-Limiting Acneiform Lesions in Patients With Colorectal Cancer

November 1st 2021

The first patients were dosed in a phase 2 trial for a topical gel to treat lesions in patients with colorectal cancer receiving EGFR inhibitor therapy.

Clinical Trial Launched for Preventive Breast Cancer Vaccine

October 28th 2021

Cleveland Clinic’s Lerner Research Institute has initiated a new study to examine a vaccine to prevent triple-negative breast cancer.

New Trial Initiated for Fosciclopirox in Patients With Bladder Cancer

October 26th 2021

A phase 1b trial started to study the effects of fosciclopirox in patients with newly diagnosed and recurrent bladder cancer.

Phase 1 Trial Begins for New Treatment Delivery Strategy in Pancreatic Cancer

October 22nd 2021

Celsion GmbH has initiated a phase 1 trial to analyze ThermoDox with focused ultrasound for patients with pancreatic cancer.

First Patient With NTRK Fusion-Positive Tumor Treated in Phase 2 Trial of Taletrectinib

October 19th 2021

A company focused on treating underserved patients announced that the first patient with an NTRK fusion was dosed in a phase 2 trial of taletrectinib this summer.

First Patient With Squamous Cell Carcinoma Dosed in Phase 2 Trial for Vilobelimab

October 17th 2021

The first patient was enrolled and dosed in InflaRx’s phase 2 trial of vilobelimab for the treatment of cutaneous squamous cell carcinoma.

Trial Initiated to Assess Efficacy of Cosela in Bladder Cancer

October 14th 2021

The PRESERVE 3 trial began this summer to determine efficacy of using Cosela with platinum-based chemotherapy in patients with metastatic bladder cancer.

Trial for Novel Advanced Prostate Cancer Drug Enrolls First Patient

October 11th 2021

The first patient was enrolled in a phase 2 clinical trial for the treatment of hormone-sensitive advanced prostate cancer.

Trial Initiated for Chemoprotective Agent to Treat Non-Small Cell Lung Cancer

October 10th 2021

Aileron Therapeutics, Inc. announced the initiation of a clinical trial for ALRN-6924, a treatment for patients with non-small cell lung cancer.

Milademetan Introduced for Patients With De-Differentiated Liposarcoma in Clinical Trial

October 5th 2021

A phase 3 clinical trial has begun to evaluate the efficacy and safety of milademetan in patients with de-differentiated liposarcoma.

First Patient With Lung Cancer Treated in Phase 2b Tomivosertib Trial

September 24th 2021

The first patient was treated in the phase 2b KICKSTART trial testing the safety and efficacy of tomivosertib in combination with Keytruda.

Enrollment Complete in Phase 3 MOMENTUM Myelofibrosis Trial

September 21st 2021

Sierra Oncology completed enrollment for its phase 3 MOMENTUM clinical trial for the treatment of patients with myelofibrosis.

Phase 2 BCG-Unresponsive Bladder Cancer Study Gets the OK to Start Enrollment

September 1st 2021

Patients with Bacillus Calmette Guérin-unresponsive carcinoma in-situ will be treated at the University of Chicago in a Theralase study.

First Patient Dosed in Expansion of Phase 1 Clinical Trial for Squamous Cell Carcinoma

August 31st 2021

The first patient with HPV-positive head and neck squamous cell carcinoma received their dose of in the CUE-101 phase 1b trial.

Investigational Cancer Treatment Being Evaluated in B-Cell Malignancies

August 23rd 2021

Researchers are evaluating the safety and efficacy of zandelisib, an investigational cancer therapy, for the treatment of patients with marginal zone lymphoma and follicular lymphoma who have received at least two prior therapies.

Patient Recruitment Has Begun for Trial Assessing Cosela in Metastatic Bladder Cancer

August 20th 2021

Preliminary results of the phase 2 trial assessing the safety and efficacy of Cosela with gemcitabine/platinum-based chemotherapy and Bavencio maintenance therapy for metastatic bladder cancer are expected to be released in the second half of 2022.

CURE’s Clinical Trial Corner: June 2021

June 24th 2021

As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.

CURE’s Clinical Trial Corner: May 2021

May 27th 2021

As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.

CURE’s Clinical Trial Corner: April 2021

April 29th 2021

Here is a list of some recent trials that launched within the cancer space in April.

CURE’s Clinical Trial Corner: March 2021

March 25th 2021

Here is a list of some recent trials that launched within the cancer space in March.

CURE’s Clinical Trial Corner: February 2021

February 25th 2021

Here is a list of some recent trials that launched within the cancer space in February.

CURE’s Clinical Trial Corner: January 2021

January 28th 2021

Here is a list of some recent trials that launched within the cancer space in January.

Advertisement
Advertisement